NephRx Gets Patent For Oral Mucositis Treatment
KALAMAZOO - NephRx Corporation Tuesday announced it was issued a U.S. patent for its peptide NX002 currently in preclinical development for the treatment of oral mucositis - a debilitating and often dose-limiting condition that affects more than 400,000 cancer patients who receive chemotherapy or radiation therapy in the United States each year. Current treatment options